ResearcherKaiser PermanenteNo recent work listed
Minggui Pan
Matched on ORCID iD 0000-0002-8368-6524; OpenAlex author ID A5030715815. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: none · 2022: none · 2023: 2 papers
Papers 6
- TP53 Gain-of-Function and Non-Gain-of-Function Mutations Are Associated With Differential Prognosis in Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/po.22.00570↗
- High-dimensional single-cell analysis unveils distinct immune signatures of peripheral blood in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fendo.2023.1181538↗
- Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1. Co-author DOI 10.1080/2162402x.2019.1581529↗
- Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. Co-author DOI 10.1186/s13045-019-0822-6↗
- WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PDAC. Co-author DOI 10.1186/s13046-018-0848-6↗
- Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based … Co-author DOI 10.1016/j.pan.2013.04.195↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yu Pan · 4 shared papers, 2018–2023 · strength 0.44
- Paper High-dimensional single-cell analysis unveils distinct immune signatures of peripheral blood in patients with pancreati… DOI 10.3389/fendo.2023.1181538↗
- Paper Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1. DOI 10.1080/2162402x.2019.1581529↗
- Paper WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PD… DOI 10.1186/s13046-018-0848-6↗
- Fengchun Lu · 4 shared papers, 2018–2023 · strength 0.44
- Paper High-dimensional single-cell analysis unveils distinct immune signatures of peripheral blood in patients with pancreati… DOI 10.3389/fendo.2023.1181538↗
- Paper Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1. DOI 10.1080/2162402x.2019.1581529↗
- Paper WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PD… DOI 10.1186/s13046-018-0848-6↗
- Heguang Huang · 4 shared papers, 2018–2023 · strength 0.44
- Paper High-dimensional single-cell analysis unveils distinct immune signatures of peripheral blood in patients with pancreati… DOI 10.3389/fendo.2023.1181538↗
- Paper Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1. DOI 10.1080/2162402x.2019.1581529↗
- Paper WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PD… DOI 10.1186/s13046-018-0848-6↗
- Xianchao Lin · 3 shared papers, 2018–2019 · strength 0.27
- Paper Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1. DOI 10.1080/2162402x.2019.1581529↗
- Paper WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PD… DOI 10.1186/s13046-018-0848-6↗
- Paper Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 tar… DOI 10.1186/s13045-019-0822-6↗
- Zelin Hou · 2 shared papers, 2019–2023 · strength 0.26
- Paper High-dimensional single-cell analysis unveils distinct immune signatures of peripheral blood in patients with pancreati… DOI 10.3389/fendo.2023.1181538↗
- Paper Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 tar… DOI 10.1186/s13045-019-0822-6↗
- Qinglin Fei · 2 shared papers, 2019 · strength 0.18
- Jiajing Lin · 1 shared paper, 2023 · strength 0.18
- Wen Shi · 1 shared paper, 2023 · strength 0.18
- Jianfeng Gao · 1 shared paper, 2023 · strength 0.18
- Laurel A. Habel · 1 shared paper, 2023 · strength 0.17
- Maoen Pan · 1 shared paper, 2018 · strength 0.09
- Siyu Chen · 1 shared paper, 2013 · strength 0.04
- Wei Tian · 1 shared paper, 2013 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.